Related Experiment Video
Updated: Feb 8, 2026

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
C-reactive protein-triglyceride-glucose index versus triglyceride-glucose index in predicting cardiovascular
Hongjin Wang1, Ming Yang2, Wenjing Cai3
1Department of Cardio-Thoracic Surgery, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China.
Insights
The novel C-reactive protein-triglyceride-glucose index (CTI) shows superior accuracy in predicting Cardiovascular Metabolic Multimorbidity (CMM) risk compared to the Triglyceride-Glucose (TyG) index. This finding supports CTI
Area of Science:
- Cardiovascular disease research
- Metabolic syndrome research
- Biomarker discovery
Background:
- Cardiovascular Metabolic Multimorbidity (CMM) is a major global health concern.
- Existing risk prediction models for CMM require further refinement.
- The C-reactive protein-triglyceride-glucose index (CTI) integrates inflammation and insulin resistance, offering a novel approach.
Purpose of the Study:
- To evaluate the predictive utility of the C-reactive protein-triglyceride-glucose index (CTI) for Cardiovascular Metabolic Multimorbidity (CMM) risk.
- To compare the predictive performance of CTI against the established Triglyceride-Glucose (TyG) index.
- To investigate the dose-response relationship and subgroup variations in CMM risk prediction by CTI and TyG.
Main Methods:
- Analysis of 8,487 adults aged ≥45 from the Chinese Health and Retirement Longitudinal Study (CHARLS) database (2011-2020).
- Utilized Cox regression, restricted cubic spline (RCS), and Receiver Operating Characteristic (ROC) curve analyses to assess associations.
- Conducted subgroup analyses to examine population-specific variations in predictive accuracy.
Main Results:
- Both TyG and CTI independently predicted CMM risk, with a significant dose-response association observed for both indices.
- The C-reactive protein-triglyceride-glucose index (CTI) demonstrated superior predictive accuracy compared to the Triglyceride-Glucose (TyG) index, as indicated by ROC analysis (higher AUC).
- Subgroup analyses revealed that the association of TyG with CMM risk varied by sex, smoking, and hypertension, while CTI's association differed by age, sex, and hypertension.
Conclusions:
- Elevated C-reactive protein-triglyceride-glucose index (CTI) is independently associated with an increased risk of Cardiovascular Metabolic Multimorbidity (CMM).
- CTI exhibits superior predictive performance for CMM compared to the Triglyceride-Glucose (TyG) index.
- The linear association and enhanced predictive accuracy of CTI suggest its potential clinical utility for early CMM risk stratification.
Background:
Cardiovascular Metabolic Multimorbidity (CMM), a leading global cause of mortality, lacks evidence on the predictive utility of the novel C-reactive protein-triglyceride-glucose index (CTI), which integrates insulin resistance and inflammation. This study compared CTI with the established Triglyceride-Glucose (TyG) index in predicting CMM risk.
Methods:
A cohort of 8,487 adults aged ≥45 from the CHARLS database (2011-2020) was analyzed. Over nine years, CMM events were tracked. Cox regression, restricted cubic spline (RCS), and ROC curve analyses assessed associations between TyG, CTI, and CMM risk. Subgroup analyses evaluated population-specific variations.
Results:
Among participants, 1,030 (12.14%) developed CMM. Unadjusted Cox models showed TyG (HR = 1.89, 95%CI 1.73-2.07, P < 0.001) and CTI (HR = 1.83, 95%CI 1.70-1.97, P < 0.001) predicted CMM; adjusted models confirmed persistence. A dose-response association was observed for both CTI and TyG with CMM risk. In fully adjusted models, the overall dose-response trend remained similar. ROC analysis favored CTI (higher AUC). Subgroup analyses indicated TyG's association varied by sex, smoking, and hypertension (P < 0.05), while CTI's association differed by age, sex, and hypertension (P < 0.05).
Conclusions:
Elevated CTI independently correlates with increased CMM risk, demonstrating superior predictive accuracy over TyG. Its linear association highlights potential clinical utility for early CMM risk stratification.
More Related Videos
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
08:30Intraperitoneal Glucose Tolerance Test, Measurement of Lung Function, and Fixation of the Lung to Study the Impact of Obesity and Impaired Metabolism on Pulmonary Outcomes
Published on: March 15, 2018
Related Concept Videos
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Glucose Absorption Into the Small Intestine
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...